Value in Health

Article	Citations
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	253
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force	249
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group	69
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiativ	68
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis	64
Managed Entry Agreements: Policy Analysis From the European Perspective	63
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs	61
Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary	59
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group	58
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?	54
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report	50
Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review	47
The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results	47
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach	44
Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis	44
Distributional Cost-Effectiveness Analysis Comes of Age	43
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies	42
Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations	41
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review	41
Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis	41
Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review	41
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis	41
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group	38
Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods	37
Using Virtual Reality Exposure Therapy in Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	36

Preferences for e-Mental Health Interventions in Germany: A Discrete Choice Experiment	35
Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set	35
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials	34
Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review	32
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review	32
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge	32
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom	32
A Systematic Review of Economic Evaluations Reporting the Cost-Effectiveness of Spinal Cord Stimulation	31
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling	31
Do People Favor Artificial Intelligence Over Physicians? A Survey Among the General Population and Their View on Artificial Intelligence in Medicine	30
Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study	30
The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program	29
Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey	29
A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health	29
Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings	28
Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index	28
Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force	26
Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB	26
The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis	26
Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data	26
Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?	26
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions	25
A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma	25
A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents	25
Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments	25
Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals	25
Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation	23
Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease	23
Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios	23
Did the Integrated Urban and Rural Resident Basic Medical Insurance Improve Benefit Equity in China?	23
Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment	23
Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah	22
Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols	22
Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report	22
A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation	22
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report	22
Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?	22
Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review	21
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making	21
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs	21
Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches	21
Methods Used to Identify, Test, and Assess Impact on Preferences of Bolt-Ons: A Systematic Review	21
Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective	21
An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom	21
Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations	21
Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study	21
Improving Academic Biobank Value and Sustainability Through an Outputs Focus	21
Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective	21
Mapping EQ-5D-3L to EQ-5D-5L	20
Announcing the New Definition of Health Technology Assessment	19

Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim	19
Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care	19
Indirect Economic Burden of Sickle Cell Disease	18
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review	18
Validity and Responsiveness of Preference-Based Quality-of-Life Measures in Informal Carers: A Comparison of 5 Measures Across 4 Conditions	18
Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England	18
Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users	18
Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities	18
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19	17
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis	17
Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients	17
Prevalence and Risk Factors of Primary Dysmenorrhea in Students: A Meta-Analysis	17
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force	17
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018	17
A Conceptual Framework for Life-Cycle Health Technology Assessment	17
The Roadmap for Implementing Value-Based Healthcare in European University Hospitals—Consensus Report and Recommendations	17
Acceptability and Validity of the EQ-5D in Patients Living With Dementia	17
A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults	17
A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force	16
The Preferred Qualities of Human Immunodeficiency Virus Testing and Self-Testing Among Men Who Have Sex With Men: A Discrete Choice Experiment	16
Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis	16
Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income	16
Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France	16
New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey	16
Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review	16
Quality-Adjusted Life Expectancy Norms for the English Population	16
Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management	16
Identifying Adherence Patterns Across Multiple Medications and Their Association With Health Outcomes in Older Community-Dwelling Adults With Multimorbidity	16
Nephrologist Follow-Up Care of Patients With Acute Kidney Disease Improves Outcomes: Taiwan Experience	16
Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China	15
The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review	15
Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis	15
Value of a QALY for France: A New Approach to Propose Acceptable Reference Values	15
Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis	15
Patient Preferences in the Treatment of Hemophilia A: A Best–Worst Scaling Case 3 Analysis	15
The EQ-5D-5L Value Set for England: Response to the “Quality Assurance”	15
Cost-Effectiveness of Propofol (Diprivan) Versus Inhalational Anesthetics to Maintain General Anesthesia in Noncardiac Surgery in the United States	15
Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam	15
Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis	15
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Develo	14
A Comparison of 7 Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies	14
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility	14
Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030	14
Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL	14
Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes	14
Development and Psychometric Testing of the Caregiver Self-Efficacy in Contributing to Patient Self-Care Scale	14
Patient-Reported Morbidity Instruments: A Systematic Review	14
Economic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review	14
Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis	14
Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018	14
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies	14
Economic Evaluation in Opioid Modeling: Systematic Review	14
A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature	14
Head-to-Head Comparison of the Psychometric Properties of 3 Carer-Related Preference-Based Instruments	13
Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials	13
Considering Severity in Health Technology Assessment: Can We Do Better?	13
Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB	13
Quantifying Value of Hope	13
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life	13
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands	13
Exploration of the Reasons Why Health State Valuation Differs for Children Compared With Adults: A Mixed Methods Approach	13
The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis	13
Analyzing the Pain/Discomfort and Anxiety/Depression Composite Domains and the Meaning of Discomfort in the EQ-5D: A Mixed-Methods Study	13
Qualitative Review on Domains of Quality of Life Important for Patients, Social Care Users, and Informal Carers to Inform the Development of the EQ-HWB	13
Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches	13
Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation	13
ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations	13
Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov	13
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications	13
Cost-Effectiveness of an Opioid Abuse–Prevention Program Using the Narcotics Information Management System in South Korea	13
Economic Consequences of Adult Living Kidney Donation: A Systematic Review	12
10 Years of End-of-Life Criteria in the United Kingdom	12
A Comparison of the Cost-Effectiveness of Lifestyle Interventions in Pregnancy	12
Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations	12
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare	12
Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States	12
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%	12
A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales	12
Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands	12
Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review	12

The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study	12
Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study	12
Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis	12
Valuation of Informal Care Provided to People Living With Dementia: A Systematic Literature Review	12
Fulfilling the Promise of Artificial Intelligence in the Health Sector: Let’s Get Real	11
Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment	11
The Effects of Model Misspecification in Unanchored Matching-Adjusted Indirect Comparison: Results of a Simulation Study	11
Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0	11
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia	11
Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit Patient Preferences	11
Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries	11
Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands	11
What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks	11
To What Extent Do Patient Preferences Differ From General Population Preferences?	11
A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain	11
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues	11
PNS154 THE PRISMA 2020 STATEMENT: DEVELOPMENT OF AND KEY CHANGES IN AN UPDATED GUIDELINE FOR REPORTING SYSTEMATIC REVIEWS AND META-ANALYSES	11
Measuring “Fearonomic Effects” in Valuing Therapies: An Application to COVID-19 in China	11
Quantifying the Effect of Public Activity Intervention Policies on COVID-19 Pandemic Containment Using Epidemiologic Data From 145 Countries	11
Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands	11
Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany	11
Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment	11
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force	11
Individuals’ Preferences for Esophageal Cancer Screening: A Discrete Choice Experiment	11
How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States?	10
A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients With COVID-19	10
Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling Effects	10
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations	10
Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales	10
How Much Is a Human Life Worth? A Systematic Review	10
Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia	10
PNS100 The New Reimbursement Route for Digital Health Applications (DIGA) in Germany: Critical Appraisal and First Evaluation of the Possible Effect on the German Healthcare System	10
Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment–Based Valuation Studies Affect Health Preferences?	10
A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder Deliberative Process in Latin America	10
Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories	10
Measurement Properties of the EQ-5D-Y: A Systematic Review	10
Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data	10
Healthcare Resource Utilization of Patients With COVID-19 Visiting US Hospitals	10
Cost-Effectiveness of Immediate Magnetic Resonance Imaging In the Management of Patients With Suspected Scaphoid Fracture: Results From a Randomized Clinical Trial	10
Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies	10
Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology–Based Tool to Support and Review Registries	10
Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice	10
Drug Prices and Value of Oncology Drugs in Italy	10
Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany	10
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis	10
Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products	10
An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis	10
Reporting Quality of Discrete Event Simulations in Healthcare—Results From a Generic Reporting Checklist	10
The Potential Cost-Effectiveness of a Machine Learning Tool That Can Prevent Untimely Intensive Care Unit Discharge	10
HTA13 Updating Nice Evidence Standards Framework for the Effectiveness and Economic Impact of Digital Health Technologies	10
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies	10
A Real-World Comparison of 1-Year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 Versus CoreValve Versus Evolut R	10
Are Unit Costs the Same? A Case Study Comparing Different Valuation Methods for Unit Cost Calculation of General Practitioner Consultations	10
PNS263 Pandemics and Access to Care: Use of Real-World DATA to Examine the IMPACT of COVID-19 on Pharmacy Visits in JAPAN	9
Nature and Predictors of Response Changes in Modified-Delphi Panels	9
Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States	9
Cost-Effectiveness of Food Allergy Interventions in Children: A Systematic Review of Economic Evaluations	9
Burden of Providing Informal Care for Patients with Atrial Fibrillation	9
Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019	9
Reported Challenges in Health Technology Assessment of Complex Health Technologies	9
Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma	9
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma	9
Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability	9
Developing Criteria for Health Economic Quality Evaluation Tool	9
Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia	9
Late Pregnancy Ultrasound to Screen for and Manage Potential Birth Complications in Nulliparous Women: A Cost-Effectiveness and Value of Information Analysis	9
Programmatic Costs of the Telehealth Ostomy Self-Management Training: An Application of Time-Driven Activity-Based Costing	9
An Exploratory Analysis of the “Was It Worth It?” Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment	9
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis	9
Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries	9
Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States	9
Patient-Centered Care for Women: Delphi Consensus on Evidence-Derived Recommendations	9
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group	9
Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions	9
Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease	9
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study	9
Cost-Effectiveness of Radiofrequency Denervation for Patients With Chronic Low Back Pain: The MINT Randomized Clinical Trials	9
A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample	9
The CAPACITI Decision-Support Tool for National Immunization Programs	9
Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis	9
PNS21 From Disease Burden to Healthcare Cost: Highlighting the Health Economics Aspects of the COVID-19 Pandemic	9
Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France	8
Modeling the Recovery of Elective Waiting Lists Following COVID-19: Scenario Projections for England	8
Objective Estimates of Direct-Medical Costs Among Persons Aged 3 to 38 Years With and Without Research-Defined Autism Spectrum Disorder Ascertained During Childhood: A Population-Based Birth-Cohort St	8
Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany	8
Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures	8
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England	8
Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment	8
Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration	8
The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review	8
Systematic Review of Economic Evaluations of Primary Caries Prevention in 2- to 5-Year-Old Preschool Children	8
Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods	8
Optimization Models for HIV/AIDS Resource Allocation: A Systematic Review	8
A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole	8
Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany	8